The Medtronic Newsroom is designed to assist media in finding news and information about our company.
Medtronic, founded in a Minneapolis garage in 1949 by Earl Bakken and his brother-in-law, Palmer Hermundslie, is the world’s leading maker of medical devices.
Our Mission has not changed since Earl Bakken wrote it in 1960: To contribute to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health and extend life.
More than 9 million lives are enhanced every year by a Medtronic product or therapy; that’s one every three seconds.
Medtronic is headquartered in Minneapolis, MN and operates in more than 140 countries. The company employs 46,000 people, including 5,800 scientists and engineers, pursuing research and innovation that has led to more than 28,000 patents.
|07/28/14||Medtronic Receives FDA Approval for PRESTIGE® LP Cervical Disc System|
|The PRESTIGE® LP Cervical Disc is Medtronic's Third Clinically-Proven Artificial Cervical Disc to Receive FDA Approval MEMPHIS, TENN. - July 28, 2014 - Medtronic, Inc. (NYSE: MDT) announces that it has received approval from the U.S. Food and Drug Administration (FDA) to market the PRESTIGE® LP Cervical Disc System for the treatment of single-level cervical disc disease (radiculopathy and/or myelopathy). The PRESTIGE® LP Cervical Disc is the third clinically proven artificial cervical disc in... |
|07/28/14||Medtronic Completes Acquisition of Visualase, Inc.|
|MRI-Guided Laser Ablation Technology Adds to Surgical Technologies Product Portfolio and Broader Neuroscience Leadership Position MINNEAPOLIS - July 28, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has completed the acquisition of Visualase, Inc., a privately held company based in Houston, TX, that develops and markets an FDA-approved MRI-guided laser and image guided system for minimally invasive neurosurgeries, including surgical thermal ablation. Medtronic will add Visualase'... |
|07/02/14||People with Type 2 Diabetes Achieve Superior Outcomes with Insulin Pumps vs. Multiple Daily Injections|
|Comparative Efficacy Results from the OpT2mise Trial Published in The Lancet Could Redefine Management of Insulin-Requiring Type 2 Diabetes MINNEAPOLIS - July 2, 2014 - As an example of its commitment to improving clinical outcomes for all people with diabetes, Medtronic, Inc. (NYSE:MDT) today announced the results of the OpT2mise trial, which showed that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections... |
|Receive E-mail Alerts |
|Sign up to receive e-mail alerts whenever Medtronic posts new information to the site. Just enter your e-mail address and click Submit.|